US Drugs Firm Verseon Targets £230m AIM Float

A California-based pharmaceuticals group is hoping to attract the attention of the UK's best-known fund manager by targeting a £230m stock market listing in London. Sky News understands that Verseon, which uses proprietary technology to assist in the drug discovery process, has appointed Cenkos, the investment bank, to prepare it for a listing on the juior AIM market. Cenkos has begun a roadshow of prospective investors in recent days, according to insiders, and is talking to institutions